Leerink Partnrs Has Positive Outlook for IRWD Q2 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.08). The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals' Q3 2025 earnings at $0.13 EPS and FY2026 earnings at $0.48 EPS.

Several other brokerages have also commented on IRWD. Wells Fargo & Company restated an "equal weight" rating and issued a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. JMP Securities lowered their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th. StockNews.com raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Citizens Jmp downgraded Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Finally, Craig Hallum cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Seven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $4.78.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD traded down $0.03 during midday trading on Monday, hitting $0.56. 1,043,692 shares of the company traded hands, compared to its average volume of 2,526,784. Ironwood Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $7.11. The firm has a market cap of $90.94 million, a P/E ratio of -18.80 and a beta of 0.37. The stock has a 50-day moving average price of $1.08 and a 200 day moving average price of $2.58.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company had revenue of $41.14 million for the quarter, compared to analysts' expectations of $67.02 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of Ironwood Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after acquiring an additional 3,209 shares during the last quarter. Swiss National Bank boosted its stake in Ironwood Pharmaceuticals by 2.2% in the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock worth $1,252,000 after purchasing an additional 6,000 shares in the last quarter. Teacher Retirement System of Texas grew its position in Ironwood Pharmaceuticals by 19.6% during the 4th quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company's stock valued at $190,000 after purchasing an additional 7,020 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, MetLife Investment Management LLC increased its stake in Ironwood Pharmaceuticals by 10.6% during the 4th quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 8,559 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.